Supported by an educational grant from Novartis Pharmaceuticals Corporation
Updated chronic urticaria (CU) guidelines recommend that clinicians conduct a thorough history and implement appropriate assessment tests to exclude other diseases and causes that should be considered in the differential diagnosis and, importantly, to distinguish among several subtypes of CU. Delayed and inaccurate diagnoses can lead to unnecessary or inappropriate treatment. This Specialty House Call takes a closer look at the pathophysiology of CU and the various subtypes of CU, in particular chronic idiopathic urticaria (CIU). These decisions are put into perspective via a discussion of a 52-year-old woman with CIU who was unresponsive to initial therapies. Clinicians need to appropriately assess patients’ responses to current therapies in a step-care approach and consider alternative treatment options for those who have a suboptimal response.
Allergists/immunologists, dermatologists, primary care physicians, and other healthcare providers who diagnose and manage patients with chronic urticaria
At the conclusion of this activity, participants should be better able to:
Appropriately diagnose and distinguish between acute and chronic urticaria (CU) subtypes
Implement appropriate evidence-based recommendations for a stepwise approach to the treatment of patients with CU
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Adam Friedman, MD Associate Professor of Dermatology Residency Program Director Director, Translational Research Director, Supportive Oncodermatology George Washington School of Medicine & Health Sciences Washington, DC
Dr. Friedman receives consulting fees from Aveeno, Berg LLC, Biogen, Encore Dermatology, Exeltis USA Dermatology LLC, Galderma, IntraDerm Pharmaceuticals, Lilly (Eli Lilly and Co.), L’Oreal, Novartis Pharmaceuticals Corporation, and Pfizer. He is also on the speakers’ bureaus of Janssen Pharmaceuticals, La Roche-Posay, Regeneron Pharmaceuticals, Promius Pharma, and Pfizer, and performs contracted research for Aclaris Therapeutics.
Paul Doghramji, MD Family Physician Collegeville Family Practice Pottstown Medical Specialists, Inc. Collegeville, PA
Dr. Doghramji receives consulting fees from Allergan, Ironwood Pharmaceuticals, and Merck & Co., Inc. He is also on the speakers’ bureau of Merck & Co., Inc., and holds an ownership interest in Pfizer.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education and Novartis Pharmaceuticals Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.